Key opportunities lie in reagents & consumables due to their high usage, drug discovery's large market share, and significant ...

The DNA microarray market is witnessing steady growth due to the rising demand for advanced genomic research, personalized medicine, and early disease diagnosis. The increasing prevalence of cancer, ...

In the world of gene-expression profiling, microarrays reign, but they are not without drawbacks. Microarrays have trouble with low-abundance transcripts and unidentified genes, for instance.

In the post-genomic era, long non-coding RNAs (lncRNAs) have emerged as critical regulators in various cancers and hold potential as minimally invasive diagnostic biomarkers. This study aimed to ...

Site-specific therapy guided by gene-expressing profiling (GEP) could improve outcomes for patients with previously untreated cancers of unknown primary (CUP), Chinese researchers suggested. In their ...

Short interval circulating tumor DNA (ctDNA) kinetics as a predictor of tumor response in patients with gastrointestinal (GI) cancer receiving immune checkpoint inhibitor (ICI)-based treatment. This ...

The research community's rapid acceptance of microarrays notwithstanding, technical challenges remain. Biochip developers continue to grapple with these issues while upgrading their offerings and ...

Breast Cancer Index re-stratifies 21-gene assay risk groups for late distant recurrence and extended endocrine therapy benefit: Results from the BCI Registry Study. This is an ASCO Meeting Abstract ...

Computational assessment identifies probe binding errors in a widely used commercial platform for spatial transcriptomics.